SURVYR

EYPT

EyePoint, Inc.
$0.38
+$0.02 (4.83%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-97%-58%-20%+19%+58%Oct 2025Oct 2026Apr 202652w high $19.1152w low $0.39
EYPTSPY
Wall St. Highest PT $31.00 (+8114.1%) Wall St. Avg PT $8.44 (+2135.7%)
$0$11$21$32$42POC $13Hi $31Avg $8
Underwater Drawdown %Max DD -98.1%Current -98.0%
0.0%-98.1%
Relative Strength vs SPY-110.8% vs SPYUnderperforming
+127%0%-127%
1W
−$0.05 (12.23%)
1M
−$2.93 (88.60%)
3M
−$11.54 (96.83%)
6M
−$12.48 (97.07%)
YTD
−$17.89 (97.93%)
1Y
−$11.87 (96.92%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Hold
13 analysts · mean score 2.77
1 = Strong Buy · 5 = Sell
Strong Buy00%
Buy215%
Hold1077%
Underperform00%
Sell18%
Wall Street consensus
Analyst price targets
Current price$0.38
Average target$8.44
+$8.06 (+2135.7%) upsideaverage target vs current price
CurrentAverageMedian
Low$0.50
Median$4.00
High$31.00
12-month Wall Street target range
Recent analyst rating changes · 30
Downgrade
2026-10-20 · Laidlaw & Co. downgraded EYPT from Buy to Hold
Reiterated
2026-10-20 · RBC Capital reiterated Sector Perform on EYPT
Downgrade
2026-10-20 · Guggenheim downgraded EYPT from Buy to Neutral
Downgrade
2026-10-20 · JP Morgan downgraded EYPT from Neutral to Underweight
Reiterated
2026-10-20 · HC Wainwright & Co. reiterated Neutral on EYPT
Downgrade
2026-09-02 · TD Cowen downgraded EYPT from Buy to Hold
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$33.9M
P/E (next 12 months, estimated)-0.2
52-week range$0.39 – $19.11
Revenue growth (latest quarter vs a year ago)-90.5%
Dividend yieldNo dividend
Analyst consensusHold (8)
Average analyst price target$8.44 (+2136%)

What they do

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for EYPT yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

EYPT earningsNext report in 7 days
Next report · quarter Sep 2026
Wed Nov 4, 2026Before the open
EPS consensus-$0.93 range -$1.19–-$0.79
Revenue consensus$233.1K 13 analysts
Last 4 quarters · EPS vs estimate
Aug 5, 2026-$1.09est -$0.96−13.9%Below estimates
May 6, 2026-$0.99est -$0.81−22.5%Below estimates
Mar 4, 2026-$0.81est -$0.75−8.0%Below estimates
Nov 5, 2025-$0.85est -$0.77−10.2%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-25 14:07:27 ET
24-1125-0325-0525-0825-1126-0326-0526-08-1.090.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$507.0K-90.5%
2026-03-31$696.0K–
2025-12-31$620.0K–
2025-09-30$966.0K–
2025-06-30$5.3M–

News & catalysts

More news
EyePoint crashes as pivotal wet AMD trial fails, prompting 53% workforce cut
Investing.com · Oct 19
EyePoint's Duravyu Misses Primary Endpoint in Second Phase 3 Wet AMD Trial; Shares Fall Pre-Bell
MT Newswires · Oct 19
EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD
GlobeNewswire · Oct 19
Rating changes
Downgrade
2026-10-20 · Laidlaw & Co. downgraded EYPT from Buy to Hold
Reiterated
2026-10-20 · RBC Capital reiterated Sector Perform on EYPT
Downgrade
2026-10-20 · Guggenheim downgraded EYPT from Buy to Neutral
Downgrade
2026-10-20 · JP Morgan downgraded EYPT from Neutral to Underweight
Reiterated
2026-10-20 · HC Wainwright & Co. reiterated Neutral on EYPT
Downgrade
2026-09-02 · TD Cowen downgraded EYPT from Buy to Hold

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Zaderej Karen L.
Director · 2026-08-18
Buy
$52.3K
None
None · None
Sell
–

Stats refreshed 2026-10-25 14:07:27 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026